Why Partner with Biotle
Focus on high unmet needs across oncology and autoimmune indications, with formats and formulations (including SC) that can improve access and adherence.
Programs rooted in disease biology and immune pathway insight, designed to intervene at critical nodes for targeted, effective, and safer outcomes.
TriME® bi-/tri-specific architecture anchored by a fully human CD3ε with tuned affinity to balance potent activity and safety, with strong manufacturability.
Our Collaboration Focus
Strategic Co-Development
Jointly advance Biotle assets or co-create new bi/tri-specific antibodies leveraging complementary target biology, translational tools, or clinical capabilities.
In-Licensing / Asset Acquisition
Selective evaluation of external assets that align with our mechanism-driven strategy and can benefit from TriME® engineering or our therapeutic area expertise.
Out-Licensing / Regional Deals
Partner select programs to expand geographic reach, accelerate development, and maximize patient impact where partners offer clear commercial or clinical scale.
Areas of Interest
- Oncology: Solid and hematologic tumors where multispecific immune engagement can overcome resistance or heterogeneity.
- Autoimmune Diseases: Pathways where selective immune recalibration may yield durable disease control.
- Modalities & Enablers: Antibodies, multispecific formats, enabling ADC/linker-payload collaborations, and translational platforms complementary to TriME®.
How to Engage
We welcome discussions with biopharma companies, research institutes, and platform innovators. Share a brief overview of your asset or capability focus, stage, and partnering goals.
Please contact us to explore partnering opportunities.